Pharmaceutical company Ribo have reported initial results from its Phase IIa trial of vortosiran in chronic coronary artery disease patients in Europe.

The post Ribo reports vortosiran Phase IIa trial results for coronary artery disease appeared first on Clinical Trials Arena.